FREMONT, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) today announced that it has selected PrecisionMed, Inc., a contract research organization (CRO) with expertise in the collection and management of human biological samples. PrecisionMed will support Ciphergen in its upcoming clinical trials for its ovarian tumor triage test, including the Ovarian PC1 Biomarker Clinical Trial.
